BioSystems International Raises $ 4.6 Million Venture Capital for New Diagnostics in Cancer
Published: Oct 29, 2008
The signing of the investment agreement represents one of the biggest VC deals in the diagnostics research sector within this year. “BSI SAS and its investors pursue a long-term and lasting investment strategy. The renewed commitment strengthens our status as innovator in the field of cancer diagnosis,” said Jean-Pierre Tirouflet, Chief Executive Officer of Biosystems International. Laszlo Takacs, Chief Scientific Officer added : “Benchmarks, preceding the financial agreement, demonstrated the company´s potential as a market leader in the field of monoclonal antibody based cancer diagnostics”.
“The decision to follow our investment in Biosystems International is based on the recent technology validation success. We are now entering in the diagnostic product development phase for early cancer diagnosis. This phase corresponds to a significant increase in value, since Biosystems is targeting cancer indications with particularly high unmet medical need. We are very pleased to have received validation of this strategy by a pharmaceutical partner” explained Jean-Yves Nothias from SGAM AI.
“We are excited to expand our endeavors to the diagnostics field, investment into Biosystems International and the purchase of first refusal rights for the distribution of BSI’s cancer diagnostics on our market is one of the first moves to achieve our long term goal” added the Business Development Director of the Pharmaceutical company.
About Biosystems International
Biosystems International (BSI) is a biotechnology company aiming to become a world leader in the discovery and development of novel diagnostics for diseases with critical unmet needs. Using our proprietary monoclonal antibody proteomics process BSI rapidly discovers novel biomarkers and corresponding antibodies in a single step. The company is currently focused on the discovery and development of diagnostic tests in the areas of cancer and metabolic diseases as well as the development and commercialization of antibody arrays for plasma proteome profiling.
Safe Harbor Statement
Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the company assumes no responsibility to update any such forward looking statements.
Biosystems International Laszlo Takacs, CSO + 33 (0)1 60 87 89 31 Email: firstname.lastname@example.org
Source: Biosystems International